INFORMACIONES PSIQUIÁTRICAS 246

Informaciones Psiquiátricas 2022 - n.º 246 59 12. Canuso CM, Goldstein JM, Wojcik J, Daw- son R, Brandman D, Klibanski A, Schil- dkraut JJ, Green AI. Antipsychotic medi- cation, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychia- try Res. 2002 Aug 5;111(1):11-20. doi: 10.1016/s0165-1781(02)00123-3. PMID: 12140115. 13. Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry. 2004 Dec;65(12):1607-18; quiz 1590, 1760-1. doi: 10.4088/jcp. v65n1205. PMID: 15641865. 14. Bhuvaneswar CG, Baldessarini RJ, Har- sh VL, Alpert JE. Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review. CNS Drugs. 2009 Dec;23(12):1003-21. doi: 10.2165/11530020-000000000-00000. PMID: 19958039. 15. Montejo AL, Majadas S. Implicaciones clínicas de la hiperprolactinemia. En: Ezcurra J, González-Pinto A, Gutierrez Fraile M. (editores). La Salud Física en el enfermo psiquiátrico. Madrid, Aula médica Ediciones; 2008 (299-315). 16. Grinshpoon A, Barchana M, Ponizovsky A, Lipshitz I, Nahon D, Tal O, Weizman A, Levav I. Cancer in schizophrenia: is the risk higher or lower? Schizophr Res. 2005 Mar 1;73(2-3):333-41. doi: 10.1016/j.schres.2004.06.016. Erratum in: Schizophr Res. 2005 Oct 1;78(1):115- 6. PMID: 15653279. 17. Stefan Leucht, Tonja Burkard, John H Henderson, Mario Maj, Norman Sarto- rius. Physical Illness and Schizophrenia. A Review of the Evidence. New York, Cambridge University Press; 2007. 18. Montejo ÁL, Arango C, Bernardo M, Ca- rrasco JL, Crespo-Facorro B, Cruz JJ, Del Pino J, García Escudero MA, García Rizo C, González-Pinto A, Hernández AI, Martín Carrasco M, Mayoral Cleries F, Ma- yoral van Son J, Mories MT, Pachiarotti I, Ros S, Vieta E. Spanish consensus on the risks and detection of antipsycho- tic drug-related hyperprolactinaemia. Rev Psiquiatr Salud Ment. 2016 Jul- Sep;9(3):158-73. English, Spanish. doi: 10.1016/j.rpsm.2015.11.003. Epub 2016 Feb 24. PMID: 26927534. 19. Citrome L. Current guidelines and their recommendations for prolactin moni- toring in psychosis. J Psychopharma- col. 2008 Mar;22(2 Suppl):90-7. doi: 10.1177/0269881107087373. PMID: 18477625. 20. Peveler RC, Branford D, Citrome L, Fitz- gerald P, Harvey PW, Holt RI, Howard L, Kohen D, Jones I, O'Keane V, Pariente CM, Pendlebury J, Smith SM, Yeomans D. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychophar- macol. 2008 Mar;22(2 Suppl):98-103. doi: 10.1177/0269881107087346. PMID: 18477626. 21. Bobes-García J, Saiz-Ruiz J, Bernardo- Arroyo M, Caballero-Martínez F, Gilaber- te-Asín I, Ciudad-Herrera A. Delphi con- sensus on the physical health of patients with schizophrenia: evaluation of the re- HIPERPROLACTINEMIA INDUCIDA POR ANTIPSICÓTICOS EN RESIDENTES DE UN CENTRO SOCIOSANITARIO